For example, an NLRP1 inflammasome inhibitor may be effective in patients with LN complicated by arthritis or erythema; an NLRP3 inflammasome inhibitor may be more effective in LN patients with NP-SLE. This evidence concerns the gene NLRP1 and systemic lupus erythematosus.